(Q37362435)

English

The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options

scientific article published on February 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

1 reference

Europe PubMed Central

The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

0 references

anti-retroviral agent

0 references

Antonella d'Arminio Monforte

4

object named as

Antonella d'Arminio Monforte

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

author name string

Lidia Gazzola

1

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Camilla Tincati

2

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Giusi Maria Bellistrì

3

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Giulia Marchetti

5

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

language of work or name

0 references

publication date

1 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

48

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

328-337

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Restoration of the immune system with anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

CD4 cell counts at the third month of HAART may predict clinical failure.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Nitroblue Tetrazolium Test in Hodgkin Disease and Other Malignant Lymphomas

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Response to combination antiretroviral therapy: variation by age.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: evidence of active replication in monocytes/macrophages and lymphocytes

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

The Impact of Adherence on CD4 Cell Count Responses Among HIV-Infected Patients

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Improvement of interleukin 2 production, clonogenic capability and restoration of stromal cell function in human immunodeficiency virus-type-1 patients after highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Immunodysregulation of HIV disease at bone marrow level.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

T-cell homeostasis alteration in HIV-1 infected subjects with low CD4 T-cell count despite undetectable virus load during HAART.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

A potential role for interleukin-7 in T-cell homeostasis

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

HIV disease: fallout from a mucosal catastrophe?

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Viral suppression and immune restoration in the gastrointestinal mucosa of human immunodeficiency virus type 1-infected patients initiating therapy during primary or chronic infection

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Collagen deposition limits immune reconstitution in the gut

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Class-sparing regimens for initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection.

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV‐1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Untangling the Immunological Implications of Nadir on CD4+ Cell Recovery during Suppressive Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Editorial Commentary:Immunological Nonresponse to Highly Active Antiretroviral Therapy in HIV‐Infected Subjects: Is the Bone Marrow Impairment Causing CD4 Lymphopenia?

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Changes in thymic function with age and during the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

HIV Infection and the Gut: Scarred for Life?

1 reference

https://api.crossref.org/works/10.1086%2F695852

21 January 2018

Identifiers

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37362435&oldid=2108590749"